ASCO 2026 | Tisa-cel in pediatric & young adult patients with HR B-ALL and MRD after frontline consolidation
In this video, Shannon Maude, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, provides insight into the COG AALL1721/CASSIOPEIA trial (NCT03876769) evaluating the use of tisagenlecleucel (tisa-cel) in pediatric and young adult patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) and measurable residual disease (MRD) positivity at the end of frontline consolidation. Although efficacy data appear promising, longer follow-up is needed to confirm 5-year disease-free survival (DFS). This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We conducted a trial that we have just done a primary analysis of in that group of patients, and the reason, the rationale for that is that those patients historically have had very poor outcomes with that persistent disease at the end of consolidation with a five-year disease-free survival (DFS) on a historical Children’s Oncology Group trial of just 39%. So in those patients, after they had persistent MRD at the end of consolidation, they were enrolled on a trial of tisa-cel...
We conducted a trial that we have just done a primary analysis of in that group of patients, and the reason, the rationale for that is that those patients historically have had very poor outcomes with that persistent disease at the end of consolidation with a five-year disease-free survival (DFS) on a historical Children’s Oncology Group trial of just 39%. So in those patients, after they had persistent MRD at the end of consolidation, they were enrolled on a trial of tisa-cel. And they received it after just about four months, four to five months of chemotherapy, and then were monitored for response after that. We looked at both MRD negative conversion rate, but more importantly, we were looking at longer-term outcomes at disease-free survival and overall survival. At this point, the follow-up is about 38 months. So the five-year DFS is not quite mature. But at this time, we’re seeing a three-year DFS of 71% and a projected five-year DFS of 64%. But of course, we need longer follow-up to confirm that five-year DFS.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
